You are here

  • Home
  • Archive
  • Volume 34, Issue Suppl 1
  • 526 The predictive role of platinum-based chemotherapy combinations on the effectiveness of PARP-inhibitors as maintenance therapy in the platinum-sensitive recurrent ovarian cancer: an observational MITO study

Article Text

Article menu
Download PDFPDF
Poster and E-Posters
06. Ovarian cancer
526 The predictive role of platinum-based chemotherapy combinations on the effectiveness of PARP-inhibitors as maintenance therapy in the platinum-sensitive recurrent ovarian cancer: an observational MITO study
  1. Veronica Agostinelli1,
  2. Lucia Musacchio2,
  3. Floriana Camarda2,
  4. Sandro Pignata3,
  5. Sabrina Chiara Cecere3,
  6. Giorgio Valabrega4,
  7. Valentina Tuninetti4,
  8. Francesco Raspagliesi5,
  9. Grazia Artioli6,
  10. Giorgia Perniola7,
  11. Chiara Cassani8,
  12. De Angelis Carmine9,
  13. Claudia Marchetti2,
  14. Mariagrazia Distefano2,
  15. Roberto Angioli10,
  16. Gennaro Cormio11,
  17. Serafina Mammoliti12,
  18. Elisa Picardo12,
  19. Giovanni Scambia2 and
  20. Domenica Lorusso2
  1. 1Università Politecnica delle Marche – AUO delle Marche, Ancona, Italy
  2. 2IRCCS Policlinico Universitario Fondazione Agostino Gemelli, Roma, Italy
  3. 3Unità Operativa Oncologia Medica Uro-Ginecologica Istituto Tumori di Napoli, Napoli, Italy
  4. 4SCDU Oncologia Ospedale Mauriziano di Torino – Università degli Studi di Torino, Torino, Italy
  5. 5Oncologia Ginecologica Istituto Nazionale dei Tumori, Milano, Italy
  6. 6Oncologia Ginecologica Ospedale Ca’ Foncello, Marca Trevigiana, Treviso, Italy
  7. 7Università La Sapienza, Roma, Italy
  8. 8Ginecologia oncologica Policlinico San Matteo, Pavia, Italy
  9. 9Università Federico II, Napoli, Italy
  10. 10Policlinico Campus Biomedico, Roma, Italy
  11. 11Università degli Studi di Bari, Bari, Italy
  12. 12IRCCS Azienda Ospedaliera Universitaria San Martino, Genova, Italy

Abstract

Introduction/Background State of the art therapy for recurrent platinum sensitive and PARP inhibitors (PARPi) naïve ovarian cancer (OC) patients includes platinum-based chemotherapy (carboplatin single agent or combined with paclitaxel, gemcitabine or pegylated liposomal doxorubicine) followed by PARPi as maintenance. Aim of the present study is to assess the predictive role of different platinum-based CT combinations on the effectiveness of PARPi in patients with platinum sensitive recurrent OC.

Methodology This retrospective observational study included relapsed OC patients that received platinum-containing regimen followed by PARPi as maintenance, at the time of first or subsequent platinum sensitive recurrence. Primary endpoints were progression free survival (PFS) and overall survival (OS).

Results Among 519 patients enrolled, 16.2% (84) received carboplatin as monotherapy and 80% (415) a doublet of platinum-based CT. Specifically, 16.4% (86) patients were treated with platinum-paclitaxel, 30.6% (159) with platinum-pegylated liposomal doxorubicin (PLD) and 32.8% (170) with platinum-gemcitabine. No statistical difference was found in terms of PFS between patients treated with the platinum-monotherapy and those treated with a doublet (mPFS 13.6 vs 14.4 months), but patients who received doublet had longer OS (mOS 29.7 vs 50.8 months; HR 0.6, p=0.03). According to specific CT doublets, no statistical difference was found in terms of PFS and OS, but a trend toward an increase in PFS was reported in patients treated with platinum-PLD. Specifically, a longer PFS was found in patients treated with platinum-PLD compared to platinum-gemcitabine (mPFS 17.2 vs 13 months) (figure 1).

Conclusion Regardless of the type of associated drug or whether monotherapy is used, platinum remains the drug that most correlates with the effectiveness of PARP inhibitors. However, the combination platinum-PDL seems to be the most advantageous, especially when compared to platinum-gemcitabine.

Disclosures The authors have the following conflict of interests: F.S.: GSK, MSD, Astrazeneca, Roche; C.D.A.: Novartis, Daiichi Sankyo, GILEAD, GSK, Astrazeneca, Roche, Pfizer, Seagen; G.S.: Clovis, MSD, Tesaro, Johnson&Johnson; D.L.: Clovis, MSD, GSK, Gemnab, Astrazeneca, Immunogen, Oncainvest, Pharmamar. The other authors declare have no conflict of interest.

Abstract 526 Figure 1
Abstract 526 Figure 1

https://doi.org/10.1136/ijgc-2024-ESGO.664

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.